Standout Papers

Idelalisib, an inhibitor of phosphatidylinositol 3-kinase p110δ, for relapsed/refractory chronic ly... 2014 2026 2018 2022 462
  1. Idelalisib, an inhibitor of phosphatidylinositol 3-kinase p110δ, for relapsed/refractory chronic lymphocytic leukemia (2014)
    Jennifer R. Brown, John C. Byrd et al. Blood

Immediate Impact

7 from Science/Nature 75 standout
Sub-graph 1 of 22

Citing Papers

JAK inhibition enhances checkpoint blockade immunotherapy in patients with Hodgkin lymphoma
2024 StandoutScience
CAR T Cells and T-Cell Therapies for Cancer
2024 Standout
3 intermediate papers

Works of Thomas M. Jahn being referenced

Idelalisib, an inhibitor of phosphatidylinositol 3-kinase p110δ, for relapsed/refractory chronic lymphocytic leukemia
2014 Standout
A Phase 1 Study Of The Selective PI3Kδ Inhibitor Idelalisib (GS-1101) In Combination With Therapeutic Anti-CD20 Antibodies (Rituximab or Ofatumumab) In Patients With Relapsed Or Refractory Chronic Lymphocytic Leukemia
2013

Author Peers

Author Last Decade Papers Cites
Thomas M. Jahn 625 428 211 237 22 725
Elizabeth Bilotti 573 451 202 231 29 814
Kerstin Allen 460 465 241 255 17 733
A. M. Liberati 464 352 155 116 19 670
Sandra Kanan 518 460 287 86 23 743
Silvia Martinelli 364 191 219 222 27 617
Jennifer Orchard 580 432 283 98 16 730
Sasanka M. Handunnetti 535 482 148 107 23 712
Marwan Kwok 513 417 272 310 15 850
Renee Leduc 454 392 172 177 31 659
Anton Parker 422 303 228 277 24 659

All Works

Loading papers...

Rankless by CCL
2026